Paysign (PAYS +1.84%) stock is surging higher in Wednesday's trading. The healthcare fintech services company's share price was up 35.8% as of 2:20 p.m. ET. At the same point in the daily session, the S&P 500 was up 0.7% and the Nasdaq Composite was up 0.9%.
Paysign is likely getting a boost from bullish momentum for the broader market today, but the company's recent earnings report is the real catalyst behind today's explosive gains. On the other hand, the stock is still down roughly 1% across 2026's trading despite today's rally.
Image source: Getty Images.
Paysign posts Q4 sales beat
Paysign published its fourth-quarter results after the market closed yesterday and reported sales that topped Wall Street's expectations. The company posted sales of $22.76 million in the period, beating the average analyst estimate's target for sales of $21.55 million. Meanwhile, earnings of $0.02 per share came in line with Wall Street's forecast. Revenue for the period was up nearly 26% year over year, and management's forward guidance suggests that strong sales momentum is poised to continue through this year.
NASDAQ: PAYS
Key Data Points
The market thinks Paysign's forward guidance is a gamechanger
For 2026, Paysign expects its sales to be between $106.5 million and $110.5 million, with momentum in both its pharmaceuticals and plasma verticals seen as equal contributors to the expansion. Hitting the midpoint of that guidance range would mean posting annual revenue growth of approximately 32.5%.
Meanwhile. net income is projected to come in between $13 million and $16 million -- up from $7.55 million last year. In addition to strong sales growth ,the projected earnings jump is being supported by expansion for gross margins. With management delivering a stronger-than-expected sales outlook and margins on an upward trend, the market could continue to reward Paysign.
